Cannabis and Hemp Industry Investment News
Canopy Growth Corporation has exercised options valued at more than $1.535 million and now holds in excess of 42 million shares. AC8 is well advanced ...
The company is targeting the treatment of chronic pain in Australia while exploring global export opportunities and expansion into additional medical ...
PCI Pharma has manufactured the first engineering batch of AusCann’s medical cannabis hard shell capsules for treatment of chronic pain, bringing the ...
What are you searching for? viewAusCann Group Holdings Ltd This purchase follows recent buying from the company’s board’s chairman. MacLeman is servin...
What are you searching for? viewAusCann Group Holdings Ltd The purchase follows the recent appointment to CEO of ex Teva Pharmaceutical executive, Ido...
Ido Kanyon will replace interim CEO Dr Paul MacLeman on 22 May 2019. NYSE-listed Teva Pharmaceutical generated over $20 billion in revenue in FY17 () ...
AC8 has all the necessary licenses to grow and manufacture cannabinoid medicines in Australia. The company's first product line is medicinal cannabis ...
() (OTCQX:ACNNF) aims to produce high-quality, economical, and clinically-validated cannabinoid medicines. It has a vertically integrated strategy beg...
Quentin Megson will serve jointly in the role with existing company secretary Susan Hunter. The company aims to produce high-quality and clinically va...
The facility will support the development of existing and new cannabinoid formulations. AusCann holds the full set of necessary licences to grow and m...
DayaCann is a 50:50 joint venture formed by AusCann and Chilean partner Fundación Daya. Khiron will pay DayaCann US$1.2 million () through its DayaCan...
Executive director Dr Paul MacLeman will act as interim CEO from January 1, 2019 until a full-time appointment is made by the board. The company is ex...
The company's first product line is medicinal cannabis hard shell capsules. The proprietary solid hard shell capsules are for the treatment of chronic...
What are you searching for? viewAusCann Group Holdings Ltd The online education resources aim to bring awareness to medical professionals. Yesterday, ...
The companies will collaborate on activities to develop cannabinoid medicines as a medical option in Chile. Khiron is listed on the TSX Venture Exchan...
AusCann is transitioning from a start-up company focused on product development to a pharmaceutical production and sales business. Dr MacLeman has ove...
The company aims to release its first medicinal cannabis products in FY2019. The cannabis sector in the US is gaining investor's attention () (OTCQX:A...
What are you searching for? viewAusCann Group Holdings Ltd Elaine Darby, managing director of Auscann Group Holdings Ltd (), spoke to Proactive Invest...
Auscann has a vertically integrated strategy beginning with cultivation and production, through to manufacture and distribution of products. Partners ...
The company is a vertically integrated player thanks to early-mover partnerships. The company is presenting at the upcoming ASX Small and Mid-Cap Conf...
